Who is sponsoring NCT03429517?

NCT03429517 is sponsored by Assiut University.

What drugs are being tested in NCT03429517?

Interventions in NCT03429517: Lipogram.

What condition does NCT03429517 study?

NCT03429517 studies Dyslipidemia Associated With Acute Coronary Syndrome.

Is NCT03429517 still recruiting?

NCT03429517 is currently status unknown. Last updated 10 May 2019.

Last reviewed 2019-05-10 · How we verify

NCT03429517

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levels of Triglycerides and HDL-C in ACS Patients

Status unknown Last updated 10 May 2019

What this trial tests

trial testing Lipogram in Dyslipidemia Associated With Acute Coronary Syndrome in 120 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
1 June 2019

1 June 2020

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 June 2018
Primary completion	1 June 2019
Estimated completion	1 June 2020
Sites	2 locations across Egypt

Drugs / interventions tested

Lipogram

Conditions studied

Dyslipidemia Associated With Acute Coronary Syndrome — all drugs for Dyslipidemia Associated With Acute Coronary Syndrome →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Dyslipidemia Associated With Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background Changes in high-density lipoprotein cholesterol and triglyceride levels have been linked to residual cardiovascular risk, whereas non-high density lipoprotein levels have been shown to be more predictive of cardiovascular risk than are low-density lipoprotein cholesterol levels. We aimed to investigate the impact of high density lipoproteins, triglyceride, and non-high density lipoproteins levels on acute coronary syndrome risk with on-target low density lipoproteins levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03429517 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 10 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03429517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing